key: cord-0275242-drmzue1n
authors: Desikan, Rajat; Linderman, Susanne L.; Davis, Carl; Zarnitsyna, Veronika; Ahmed, Hasan; Antia, Rustom
title: Modeling suggests that multiple immunizations or infections will reveal the benefits of updating SARS-CoV-2 vaccines
date: 2022-05-23
journal: bioRxiv
DOI: 10.1101/2022.05.21.492928
sha: 6592f462f5a8eccb8279d91e75fe4cb2fa6bb6ce
doc_id: 275242
cord_uid: drmzue1n

When should vaccines to evolving pathogens such as SARS-CoV-2 be updated? Our computational models address this focusing on updating SARS-CoV-2 vaccines to the currently circulating Omicron variant. Current studies typically compare the antibody titers to the new variant following a single dose of the original-vaccine versus the updated-vaccine in previously immunized individuals. These studies find that the updated-vaccine does not induce higher titers to the vaccine-variant compared with the original-vaccine, suggesting that updating may not be needed. Our models recapitulate this observation but suggest that vaccination with the updated-vaccine generates qualitatively different humoral immunity, a small fraction of which is specific for unique epitopes to the new variant. Our simulations suggest that these new variant-specific responses could dominate following subsequent vaccination or infection with either the currently circulating or future variants. We suggest a two-dose strategy for determining if the vaccine needs updating and for vaccinating high-risk individuals.

SARS-CoV-2 ('CoV-2' hereafter) has caused the most severe pandemic since influenza in 1918 50

(approximately half a billion confirmed cases and 6 million deaths as of 28 th April 2022 -WHO). In 51 contrast with the 1918 influenza pandemic, where no vaccines or therapeutics were available and 52

immunity was only gained following recovery from infection, vaccination has played a key role in 53 mitigating the morbidity and mortality of CoV-2 (1, 2). However, as is the case with other circulating 54 human coronaviruses, immunity does not provide lifelong protection from reinfection (3-5) and we are 55

witnessing waves of infection with new virus variants. These variants arise and spread due to a 56

combination of factors such as waning immunity (6-9) and virus evolution (10-12). The latter results in 57 both more transmissible viruses (13-16), and viruses able to escape immunity to earlier variants and 58

vaccines (16-18). In particular, the Omicron (OM) variant of CoV-2, that arose in late 2021, is much more 59 transmissible than the ancestral Wuhan (WU) (13, 15) , and in addition, OM has a panoply of mutations in 60 the spike protein (12, 16) that allow it to partially escape antibody responses to earlier variants as well as 61

Wuhan (WU) based vaccines (2). 62 63

Prima facie, we might expect that it is best to keep the vaccine updated with the current strain. For 64 example, we might expect the updated vaccine to generate higher antibody-titers to the currently 65 circulating virus in unvaccinated individuals. Indeed, the experimental data from the animal model studies 66 support this (19). However, over time, most of the population will have either been immunized or naturally 67

infected. Studies on influenza have shown that prior immunity can skew responses to subsequent infection 68 and immunization and the phenomenon has been termed original antigenic sin (OAS) (20-25). 69

Understanding of the implications of OAS for CoV-2 vaccination requires integrating experimental and 70

clinical studies with mathematical models. A number of elegant experimental and observational studies 71

show that prior immunity has unexpected effects on the outcome following boosting with different 72 vaccines (26-28), and in particular suggest that updating the vaccine to match the circulating variant does 73 not enhance the antibody titer to the circulating variant any more than the original vaccine. We focus on 74 the OM-vaccine study by Gagne et al. (28) as the pattern of boosting observed was very similar to the 75 study using the vaccine based on the Beta variant (27). 76 77

The Gagne study (28) used a macaque primate model system to compare the boosting of immunity 78 with a WU-versus an updated OM-vaccine. Primates were first given two vaccine doses of the currently 79 used mRNA-1273 vaccine (WU-vaccine), which encodes a spike protein derived from the ancestral 80

Wuhan virus variant, to mimic prior immunity of vaccinated humans. These two vaccinations (#1 and #2) 81 resulted in a high titer of antibodies against the WU virus, and significantly lower titers against the OM 82 variant (see Fig 3A) . Over time the antibody titers to both WU and OM viruses waned significantly, and 83

at week 41 the animals were boosted with a third vaccination, either with the original WU-vaccine 84

(vaccination regime WU-WU-WU) or an updated OM-vaccine that incorporated spike protein antigen 85 from the OM virus (regime WU-WU-OM). This allowed them to determine whether updating the vaccine 86 would produce higher titers to the OM-virus. Surprisingly, their results showed that both WU-WU-WU 87

and WU-WU-OM resulted in similar antibody titers to the OM-virus. Also surprising was the finding that 88 both these vaccination regimes resulted in similar antibody titers against the WU-virus (albeit at higher 89 levels than to the OM-virus, as shown in Fig 3A) . These observations implied that it might not be necessary 90

to reformulate the vaccine to match the OM virus variant. 91 92

In this paper, we use computational models to better understand the rules of boosting of responses 93

to new virus variants. We develop and use computational models to analyze the results of Gagne et al.

(28) as well as data from other CoV-2 (8, 19, 29, 30) and influenza (31) studies. We show that our model 95

can capture the key features of the boosting of immunity following immunization with the WU-and OM-96

vaccines. Analyzing the dynamics of antigen, B cells, and antibodies in our simulations allows us to 97 understand the reason for the initially surprising observation that vaccination #3 with either vaccine results 98

in similar antibody titers to the OM virus. We then use this model to explore what might happen following 99 subsequent vaccinations. We find that while the level of immunity to the WU and OM viruses appears 100 equal following the initial booster with either the WU-or OM-vaccines, using the OM-vaccine may have 101 significant advantages with subsequent vaccinations or infections. Based on model predictions, we 102

suggest critical experiments that will allow us to determine whether the vaccine strain should be updated 103

to that of the circulating virus variants.

We consider an immunodynamics model for the interaction between the vaccine and the humoral 107

immune response. The model extends earlier multi-epitope models for the dynamics of antibody levels 108

following vaccination (25, 32) in the following ways. First, we incorporate two different vaccines, the 109 WU-and OM-vaccines. Second, we incorporate differences in the boosting of naïve and memory cells to 110

antigenically altered epitopes that underlie the phenomenon of original antigenic sin (23). We then used 111 the model to explore how the boosting of immune responses to the new virus variants is affected by the 112 interplay between prior-immunity to the old variant and the antigens expressed by the updated vaccines. 113 114 Epitope C (shown in orange) is common to both vaccines. Epitopes W (blue) and V (green) are unique to the WU and OM respectively. Antibodies specific to these epitopes can bind to these epitopes and prevent them from stimulating B cells for the same epitope. The different antigen states generated and the B cells they stimulate are shown in the top right and bottom panels respectively. The bottom panel illustrates that binding of antigen to B cells stimulates their clonal expansion and the production of antibodies.

The model is shown schematically in Fig 1. The WU-and OM-vaccines have unique as well as 116 shared or cross-reactive epitopes. We keep track of three types of epitopes: C, W and O denote cross-117 reactive epitopes and epitopes unique to WU-and OM-vaccines, respectively. We also keep track of B 118 cells and antibodies specific to these epitopes. B cells specific to an epitope are stimulated by cognate 119

antigen, undergo clonal expansion, and produce antibodies specific to that epitope. The response wanes 120 once the antigen is cleared. Further details, equations and parameters are described in the Materials and 121

Methods. We do not include more complex features of the selection and differentiation of B cell clones 122

and interactions with other immune cells such as follicular dendritic cells and T cells in germinal centers 123

(33, 34). This is because, at this stage, the experimental data does not include precise measurements of 124 these quantities after CoV-2 vaccination. Under these circumstances, the results of simpler models can 125 typically be more robust than those of complex models (35), and we focus on qualitative patterns observed 126

in the data rather than specific values. 127

Our model recapitulates the broad patterns of immunity generated both by natural infections and 129 vaccination with CoV-2. A wealth of data show that both natural infection with circulating CoV-2 as well 130

as vaccination induce antigen-specific humoral immune responses. We next describe how the model can 131

qualitatively describe the pattern of the humoral immune response observed in a number of studies.

As mentioned in the Introduction, prima facie we would expect that boosting of naïve individuals 134 with a vaccine based on the circulating variant will elicit higher antibody titers to this strain rather than a were compared between the groups. The WU-WU group elicited orders of magnitude higher WU titers 139 than OM titers, while the OM-OM group exhibited exactly the opposite response, much higher OM titers 140 than WU titers. Our model recapitulates this observation.

A characteristic of humoral immunity is that while antibody responses can be boosted by repeated 143 vaccination, the antibody titer saturates when immunity is high and subsequent vaccinations lead to only 144 very modest increases in antibody titers, as is shown in both in the clinical data for CoV-2 and model 145 simulations ( Fig 2B) (8, 30). We note that in our model, the saturation in the magnitude of the responses 146 occurs due to antibody binding to an epitope sterically preventing B cells specific for that epitope from 147 binding to and being stimulated by that antigen (24, 25). This saturation in antibody titers has also been 148

widely observed for other pathogens such as influenza (24, 31, 36).

Immune responses get more complex when individuals are exposed to different virus variants or 151

vaccines. These complexities have been discussed in the context of OAS following infections with 152 different strains of influenza. OAS also plays an role for CoV-2 infections, and this is seen in the clinical both the WU and OM variants in two human cohorts who were infected by the OM (BA1 variant) virus. 155

The first cohort comprised naïve individuals, and the second comprised individuals previously immunized 156

with two doses of WU-vaccines. Vaccinees showed boosting of both WU and OM antibody titers 157 compared with naïve individuals. Interestingly, the WU-vaccine also imprinted responses to the WU-158 variant, and following OM-infection, these responses reached higher titers compared with antibodies to 159 the OM variant. This is a signature of OAS, and our model reproduces a similar pattern as shown in Fig  160  2C . 161

We show data for immunization of mice with 2 doses of either the WU-or the OMvaccine. We see that high antibody titers to a given antigen (WU or OM) requires 2 vaccinations incorporating that antigen. (B) Our model recapitulates the saturation of antibody titer following repeated immunization or infection. The left panel shows data for the virus titer in naive (grey) and CoV-2 infected and recovered (black) individuals following two doses of the WU-vaccine. We see that the titer of antibodies in recovered individuals saturates after a single vaccination, while that in naive individuals is boosted by the second vaccination. The middle panel shows data following four doses of the WUvaccine and shows that the virus titer is boosted and reaches a plateau after vaccination #3. Simulations of repeated immunizations with the WU-vaccine at times indicated by the yellow triangles show that the antibody response to the WU-virus increases substantially after the first two vaccinations. Further boosts with the same vaccine results in little further increases in the titer of antibody. (C) We plot data from a human study showing that OM infection causes higher antibody titers to OM compared with WU in unvaccinated individuals (compare purple bars), but the converse in WU-vaccinated individuals (pink bars).

The most comprehensive and elegant study of boosting by vaccines with new variants are studies 164 which followed vaccination of previously immunized individuals with the original-vaccine versus the 165 updated vaccine (26-28). We focus on the OM-vaccine study by Gagne induce higher titers to WU than OM, and that the subsequent vaccination #3 with either WU-or OM-175 vaccines induce very similar fold-increases in the antibody titers to both WU and OM viruses. 

Our model simulations generated the pattern observed experimentally (Fig 3A) , and simulations 178 are shown in Fig 3B and to OM) results in a significant clonal expansion of B cells unique to OM. However, since the precursor 186 frequency of these cells prior to this immunization is low, the final titer of the response to unique epitopes 187 on OM is relatively modest. In contrast, the precursor frequency of the response to conserved epitopes is 188 high, and even though the fold boost is smaller than that to the epitopes unique to OM (due to epitope 189 masking), these cross-reactive responses form most of the total OM-specific response (see Fig 3B, C) .

The model also recapitulated the second observation, namely that vaccination #3 with the OM-192

vaccine induced similar increases in antibody titers to WU as WU-vaccination #3. This is due to the OM-193

vaccination stimulating responses to the WU epitopes despite their lower affinity, which is consistent with 194 the explanation of original antigenic sin proposed earlier (23).

The model thus shows that though the titer of antibodies to the OM epitope is similar following 197

immunization #3 with either the WU-or OM-vaccines, there are important differences. Vaccination #3 198

with the OM-vaccine results in a modest increase in OM-specific B cells and antibodies. While these form 199 a small fraction of the total response to OM, we show next that they may have a profound effect following . However, a further vaccination #4 reveals substantially higher antibody titers to OM when the OM-vaccine is used rather than the WUvaccine (compare solid light green and dashed dark green lines). The bar graph at the right shows that vaccinations #3-#5 are with the OM-vaccine (light green bars) result in much higher antibody titers to OM compared to when the WU-vaccine is used (dark green bars). (B) We plot antibody titers to the OM-specific versus conserved epitopes following WU-WU-OM-OM-OM vaccination. We see that the overall increase in titers to OM (light green line) following vaccinations #4 & #5 arises from increases in the OM-specific antibody titer (dashed green line) and responses to the conserved epitopes do not increase (dashed brown line). This is shown in the bar-plot to the right where we see the antibody titer to the OM-specific epitopes (green bars) and shared epitopes (brown bars).

We now use our model simulations to examine what would occur if we were to give additional 205 vaccinations (#4 and #5) with OM versus WU. The results are shown in Fig 4A. We see that while the 206 size of the OM response following vaccination #3 is similar whether the OM-or the WU-vaccine is used 207

(the first two bars of the bar plot on the right in Fig 4A) , the same does not hold following subsequent The strongest independent support for the prediction that two vaccinations with a new virus strain 220 is needed to reveal the boosting of antibodies to new epitopes comes from influenza H5N1 studies. In Fig  221  5 , we show clinical data from an earlier study (31) for immunization with an influenza H5N1 vaccine. 222

Volunteers were immunized with two doses of the hemagglutinin (HA) envelope protein from the H5N1 223 strain of influenza (which had not circulated in the human population). The HA protein of H5N1 has head 224 and stem domains. The head of H5N1-HA is novel and very different from that of currently circulating 225 influenza strains, while the stem shares conserved epitopes with influenza H1N1, which is circulating in 226 the human population and to which individuals have prior immunity. We see that the first dose of the H5 227

vaccine results in an increase in the antibody to the shared stem region of HA, and little discernible 228

increase in antibody to the new head region of HA (left panel of Fig 5) . However, the situation is reversed 229

following the second immunization with H5. A booster with the H5 vaccine results in substantial increase 230

in the titer to the head of H5, but little further increase in titers to the stem of HA (left panel of Fig 5) . 231

This is consistent with the results of our model (see right panel of Fig 5) and supports the hypothesis that 232

generating high antibody titers to novel antigenic sites on a virus protein that exhibits antigenic changes 233 requires two immunizations. 234 235 The left plot shows data for the fold change in antibody titer to epitopes on the head (red) and stem (black) of influenza hemagglutinin (HA) antigen following prime and boost with a H5 vaccine. The first immunization with H5 results in a larger fold increase in antibodies to the conserved stem (shared with H1 viruses), and a significant fold-increase in antibody titers to the unique head epitopes is only seen following the second H5 immunization (boost) (31).

Vaccination has played a critical role in the control of the CoV-2 pandemic worldwide (1, 2) . 238

However, a combination of waning immunity and virus evolution has resulted in large waves caused by 239 new virus variants, in particular the Delta and Omicron variants, that partly evade immunity elicited by 240 the vaccine (2, 16, 17) . The question then is, when do we need to modify the vaccine to match the 241 circulating virus variant? 242 243

Understanding the dynamics of immunity to CoV-2 and influenza are particularly challenging 244 because pre-existing immunity from earlier vaccinations and infections impacts the outcome of 245 subsequent exposures to new virus variants (20-25). The utility of computational models such as the one 246

we use is their ability to explain complex outcomes that arise from the interactions between multiple 247

factors. The integration of computational modeling to recapitulate patterns observed in multiple datasets 248

can thus play an important role, and ideally should be done in an iterative manner where the models are 249 used to understand the existing data and propose experimental tests that can allow rejection or refinement 250 of the models.

The most important findings of our paper arise from computational modeling of the patterns 253 observed in the elegant experimental study of Gagne et al. (28) , which compared how the original WU-254

vaccine versus an updated OM-vaccine boosts immunity to the currently circulating OM virus. 255

Surprisingly, their results showed that WU-WU-WU vaccination was as effective as WU-WU-OM as 256 measured by antibody titers to OM, suggesting that it was not necessary to update the vaccine at the current 257 time. We use mathematical models to address the following: what accounts for this observation, what are 258 the consequences for subsequent immunizations or infections, and how can the model be empirically 259 tested? 260 261

Our model suggested that WU-WU-WU and WU-WU-OM result in similar antibody titers to OM 262 because this response is dominated by relatively large secondary (or recall) responses to shared epitopes 263 common to OM and WU. The magnitude of this secondary response obscures the much smaller primary 264 response to new epitopes on OM that occur for the first-time following vaccination #3 with the OM-265

vaccine (but not with the WU-vaccine).

We then used our models to forecast what would happen if vaccination #3 was followed by further 268 vaccinations or infections. We found that repeated boosts (#3, #4, #5) with OM resulted in much higher 269 titers of antibodies for epitopes unique to OM, and this resulted in a much higher overall titer to OM. Our Based on this finding, we suggest the general prediction that most of the response generated 279

following the first dose of a vaccine updated to match a new virus variant consists of antibodies specific 280

to the shared antigens, and that high titer responses specific for epitopes unique to the new variant are 281 revealed only following a second immunization with the same vaccine. There may be additional 282 advantages to updating the vaccine to match new virus variants. In particular, it allows the antibody 283 response of individuals to better match future variants that arise from the current OM variant. These 284

variants may correspond to the newly arising lineages of OM (e.g., BA2, BA4, BA5), and antibody 285 responses generated by two doses of the OM-vaccine would be expected to have higher titers to these new 286 variants than if the WU-vaccine were used. Finally, we note that it may be worth considering giving two 287 doses of updated vaccines to vulnerable individuals, not only for CoV-2 but potentially also for influenza.

We now briefly mention several caveats pertaining to our study. At the current stage, we have 290

intentionally used a relatively simple model that focuses on the magnitude of the antibody response 291

following WU-and OM-vaccination. This is because at present, data on the dynamics following 292

immunization and boosting is largely limited to titers of antibodies ( include the spatial aspect of infections of the respiratory tract (51-54) as well as the dynamics of 298 production and distribution of antigen by mRNA based vaccines (55) as well as infections. As more data 299 becomes available, it will be possible to construct more nuanced and refined models of the dynamics of 300 humoral immunity as well as affinity maturation (56-62). Other directions that could be taken include 301

modeling how protection is lost as the antibody titers elicited by the different immunizations wane. Gagne 302 et al. showed that shortly after vaccination #3, both vaccines elicited similar levels of protection following 303 virus challenge, and it will be important to know if and how this protection declines over time as antibody 304 titers wane (7, 63, 64) . In particular, we would like to know if the protection against OM infections 305 generated by WU-WU-OM-OM would decline slower than protection following WU-WU-WU-WU. 306

Furthermore we would like to evaluate this for different components of protection, namely, protection 307 from infection versus protection from severe disease (65). Another direction is to explore the roles of CD8 308

T cells (66-68), particularly those specific to the CoV-2 nucleocapsid protein (69) and other viral proteins 309

which may be conserved across CoV-2 strains and might thus play a valuable role in inducing potent 310

cross-reactive immunity.

In summary, the current study uses models to explore some of the complexities associated with 313 choosing when to update the CoV-2 vaccine to match antigenic changes in the virus. Model simulations 314 explain the outcomes of multiple studies of boosting of immunity to CoV-2 and generate qualitatively 315 robust predictions that have implications for determining when to update the CoV-2 vaccine. Based on 316

our results, we suggest that it is not sufficient to monitor the level of immunity to the new variant after a 317 single boost, but that further vaccinations with the updated vaccine should be administered in studies that 318 evaluate the benefit of updating vaccines. This general conclusion may also be relevant for the boosting 319 of immunity to other respiratory viruses such as influenza. An important function of models is that they 320 not only guide the design of vaccination regimes, but also that they are falsifiable, and we have suggested 321 experimental tests that can either confirm or reject the model. Applied to the current debate on updating 322

the CoV-2 vaccine, we propose that a second boost with the OM vaccine be incorporated in studies would 323 result in substantially higher OM-specific antibody titers than if the WU vaccine strain were used. 324

As mentioned in the text, we extend a multi-epitope model developed earlier (25, 32) to consider 326 the dynamics of boosting responses to new strains of influenza. As mentioned in the Results, the model 327 has the following extensions. First, we incorporate two different vaccines, the WU-and the OM-vaccines. 328

Second, we incorporate differences in the boosting of naïve and memory cells to antigenically altered 329 epitopes that underlie the phenomenon of original antigenic sin (23). We now describe the model in detail.

Because the available longitudinal data focuses on antibody titers, we use a minimal model that 332

considers 2 vaccine antigens for the WU-vaccine and the OM-vaccine. The antigens WU and OM each 333

have two types of epitopes (Fig 1) : the 'C' epitopes are conserved across both WU and OM, and the 'W' 334

and 'O' epitopes are unique to the WU and OM respectively. We let the ratio of conserved to unique 335 antigen epitopes equal : ( = 1, = 5; results are qualitatively similar for other values of and ).

Binding of antibody to the different epitopes on the antigen gives us antigen states as shown in Fig 1. We 337 consider different states for antigen with antibody bound to antigen, for example OMco and OMxo 338

represents OM antigen with no antibody bound (both C and O epitopes free) and OM antigen with 339 antibody bound to the C epitope, respectively. The model also keeps track of B cells Bc, Bw and Bo which 340 make antibodies Ac, Aw and Ao specific for C, W and O epitope sites, respectively. We use the usual mass 341 action terms for binding of antigen to antibody. B cells are stimulated by cognate antigen (antigen with 342 the relevant epitope free). We further allow previously stimulated (but not naïve) B cells to be stimulated 343 by the altered epitope at a low rate. The latter is a mechanism for original antigenic sin described 344

previously (23) (2) %" = * !" * ! − * %" * " − #$ * %"

(3)

351 352 Writing -review and editing, Visualization, Supervision, and Funding acquisition.

Data and code availability 371 372

No new data or original code were reported in this paper. All model simulation and plotting codes 373

and any additional information required to reanalyze the data/simulations reported in this paper are 374 available from the lead contact upon request.

Declaration of interests 377 378

All the authors declare no competing interests. 379 380

The changing epidemiology of SARS

Progress of the COVID-19 385 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

The time course of the immune response to 388 experimental coronavirus infection of man

391 der Hoek, Seasonal coronavirus protective immunity is short-lasting

Reinfection 394 in patients with COVID-19: a systematic review

Longitudinal analysis shows durable and 400 broad immune memory after SARS-CoV-2 infection with persisting antibody responses and 401 memory B and T cells

403 Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

The 410 UPenn COVID Processing Unit

412 mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous 419 Infection

Population impact of SARS-CoV-421 2 variants with enhanced transmissibility and/or partial immune escape

Of variants and vaccines

Towards SARS-CoV-2 serotypes?

Omicron variant and booster COVID-19 vaccines. The Lancet Respiratory Medicine

Evidence that D614G Increases Infectivity of the COVID-19 Virus

The effective reproductive number of the Omicron variant of SARS-CoV-2 is 437 several times relative to Delta

Rapid epidemic 452 expansion of the SARS-CoV-2 Omicron variant in southern Africa

Reduced sensitivity 457 of SARS-CoV-2 variant Delta to antibody neutralization

Analysis of 460 SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use 461 ACE2 receptors from additional species

Boosting with variant-matched or historical mRNA 466 vaccines protects against Omicron infection in mice

Antibody landscapes 472 after influenza virus infection or vaccination

From Original Antigenic Sin to the Universal 474 Influenza Virus Vaccine

Estimating the Life Course of Influenza A(H3N2) Antibody Responses from Cross-477 Sectional Data

Antibodies with 'Original Antigenic Sin' Properties Are Valuable 479 Components of Secondary Immune Responses to Influenza Viruses

482 Influenza Immunization in the Context of Preexisting Immunity. Cold Spring Harb Perspect Med

Multi-epitope models explain how 485 pre-existing antibodies affect the generation of broadly protective responses to influenza

Safety and immunogenicity of SARS-CoV-2 variant 490 mRNA vaccine boosters in healthy adults: an interim analysis

500 Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman 501 primates

mRNA-1273 or mRNA-Omicron boost in 513 vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from 514 Omicron

Omicron infection enhances Delta antibody immunity in vaccinated 521 persons

4th Dose COVID mRNA Vaccines' Immunogenicity 525 &amp

Induction of broadly cross-530 reactive antibody responses to the influenza HA stem region following H5N1 vaccination in 531 humans

Masking of antigenic 533 epitopes by antibodies shapes the humoral immune response to influenza

Factors in B cell competition and immunodominance

Uses and Abuses of Mathematics in Biology

Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and 545 strain-specific naive B cell responses in humans

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory 549 enhanced by cross-reactive T cells

Circulating Severe Acute Respiratory Syndrome Coronavirus 552 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

557 SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Longitudinal analysis of antibody dynamics in 561 COVID-19 convalescents reveals neutralizing responses up to 16 months after infection

In vivo kinetics of SARS-CoV-2 564 infection and its relationship with a person's infectiousness

for the French COVID Cohort Investigators and French Cohort 571 Study groups, Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized 572 patients from the French COVID cohort

Germinal centre-driven maturation of B cell response to mRNA vaccination

Helper Cell Biology: A Decade of Discovery and Diseases

Dynamics of B cells in germinal centres

Germinal Center and Extrafollicular B Cell Responses in 584 Vaccination

The germinal centre B cell response to SARS-CoV-2

Germinal centres seen through the 588 mathematical eye: B-cell models on the catwalk

Imaging the different timescales of germinal center 590 selection*

Linking signaling and selection in the germinal center

A mathematical model describing 597 the localization and spread of influenza A virus infection within the human respiratory tract

Host-pathogen kinetics during influenza infection and coinfection: insights from 600 predictive modeling

Lung-resident memory B cells 605 established after pulmonary influenza infection display distinct transcriptional and phenotypic 606 profiles

How germinal centers evolve broadly neutralizing antibodies: the 610 breadth of the follicular helper T cell response

Preferential presentation of high-affinity immune complexes 612 in germinal centers can explain how passive immunization improves the humoral response

Stringency In Germinal Centers Can Explain Improved COVID-19 Vaccine Efficacies With Low 616 Dose Prime or Delayed Boost

Competitive exclusion by autologous antibodies can prevent broad HIV-1 618 antibodies from arising

Injection of antibodies against immunodominant epitopes tunes germinal 621 centers to generate broadly neutralizing antibodies

A theory of 623 germinal center B cell selection, division, and exit

Manipulating the selection forces during affinity 626 maturation to generate cross-reactive HIV antibodies

Neutralizing antibody levels are highly predictive of immune 629 protection from symptomatic SARS-CoV-2 infection

Modeling how antibody responses may determine the 631 efficacy of COVID-19 vaccines

Transition to endemicity: Understanding COVID-19

A COVID-19 peptide vaccine for the induction of SARS

CoV-2 T cell immunity

T Cell Memory: Understanding COVID-19

Comprehensive analysis of T 644 cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

649 Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective 650 Immunity

We see that the overall increase in titers to OM (light green line) following vaccinations

This is shown in the bar-plot to the right where 700 we see the antibody titer to the OM-specific epitopes (green bars) and shared epitopes

The left plot shows data for the 704 fold change in antibody titer to epitopes on the head (red) and stem (black) of influenza hemagglutinin 705 (HA) antigen following prime and boost with a H5 vaccine. The first immunization with H5 results in a 706 larger fold increase in antibodies to the conserved stem (shared with H1 viruses), and a significant fold-707

C (shown in orange) is common to both vaccines. Epitopes W (blue) and V (green) are unique to the WU 654 and OM respectively. Antibodies specific to these epitopes can bind to these epitopes and prevent them 655 from stimulating B cells for the same epitope. The different antigen states generated and the B cells they 656 stimulate are shown in the top right and bottom panels respectively. The bottom panel illustrates that 657binding of antigen to B cells stimulates their clonal expansion and the production of antibodies. We show data for immunization of mice with 2 doses of either the WU-or the OM-vaccine. We see that 662high antibody titers to a given antigen (WU or OM) requires 2 vaccinations incorporating that antigen.

(B) Our model recapitulates the saturation of antibody titer following repeated immunization or infection. 664The left panel shows data for the virus titer in naive (grey) and CoV-2 infected and recovered (black) 665individuals following two doses of the WU-vaccine. We see that the titer of antibodies in recovered 666individuals saturates after a single vaccination, while that in naive individuals is boosted by the second 667vaccination. The middle panel shows data following four doses of the WU-vaccine and shows that the green lines). However, a further vaccination #4 reveals substantially higher antibody titers to OM when 693the OM-vaccine is used rather than the WU-vaccine (compare solid light green and dashed dark green 694 lines). The bar graph at the right shows that vaccinations #3-#5 are with the OM-vaccine (light green bars) 695 result in much higher antibody titers to OM compared to when the WU-vaccine is used (dark green bars).

(B) We plot antibody titers to the OM-specific versus conserved epitopes following WU-WU-OM-OM-697